Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories
Mandate

Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories

February 15, 2021 Banking and Finance Capital Markets and Public M&A M&A

Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.

HistoCyte Laboratories’ portfolio of cell line materials provide control of immunohistochemical assays used in the diagnosis of cancer. The company has established a significant presence on important markets such as the UK and USA.

Closing is expected during early March 2021.

Vinge’s team consisted of Jonas Johansson together with Viktor Lennartsson (M&A), Albert Wållgren and Josefine Lanker (Banking and Finance) and Clara Sohlberg (Capital Markets and Public M&A).

Related

Vinge advises Consolid Equity in connection with the establishment of Petra Group

 Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

 Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

 Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026